Clinical trial
ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer
NCT00102700 · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA), Industry · Completed
Key facts
| NCT number | NCT00102700 |
|---|---|
| Title | ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer |
| Official title | A Phase II Study of ARQ 501 in Combination With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma |
| Lead sponsor | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA), Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer, Adenocarcinoma |
| Intervention type | Drug |
| Interventions | ARQ 501 in combination with gemcitabine |
| Enrollment | 66 |
| Start date | Jan 1, 2005 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2007 |
| First posted | Feb 2, 2005 |
| Last update posted | Apr 29, 2009 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: